AMENDMENT TO H.R. 5300 OFFERED BY MR. OLSZEWSKI OF MARYLAND

At the appropriate place, insert the following:

| 1 | SEC GLOBAL HEALTH RESEARCH AND DEVELOPMENT |
|----|--|
| 2 | AUTHORITY. |
| 3 | (a) In General.—The head of the relevant foreign |
| 4 | assistance agency may support and invest in research and |
| 5 | development activities that advance global health and the |
| 6 | global health security objectives of the United States. |
| 7 | (b) Research and Development Assistance.— |
| 8 | Assistance authorized under this section may be used to |
| 9 | support product development and implementation research |
| 10 | to accelerate the development, introduction, and scale-up |
| 11 | of new global health technologies, including support for— |
| 12 | (1) late-stage research and development; |
| 13 | (2) regulatory approval processes; and |
| 14 | (3) facilitating availability and access in real- |
| 15 | world settings in low- and middle-income countries. |
| 16 | (c) Priority.—In carrying out activities under this |
| 17 | section, the head of the relevant foreign assistance agency |
| 18 | shall give priority to areas in which significant innovation |
| 19 | gaps persist and where private sector investment incen- |

| 1 | tives are inadequate and public funding can play a cata- |
|----|--|
| 2 | lytic role, including the areas of— |
| 3 | (1) vaccines and prevention products for human |
| 4 | immunodeficiency virus; |
| 5 | (2) improved treatments and vaccines for tuber- |
| 6 | culosis; |
| 7 | (3) new treatments, vaccines, and vector control |
| 8 | technologies for malaria and neglected tropical dis- |
| 9 | eases; |
| 10 | (4) interventions targeting maternal and child |
| 11 | health; |
| 12 | (5) countermeasures against emerging infec- |
| 13 | tious diseases; |
| 14 | (6) strategies to address antimicrobial resist- |
| 15 | ance; and |
| 16 | (7) point-of-care diagnostics relevant to global |
| 17 | health priorities. |
| 18 | (d) Partnerships.—Activities carried out under |
| 19 | this section may be implemented through partnerships |
| 20 | with public and private entities, including product develop- |
| 21 | ment partnerships, academic institutions, international or- |
| 22 | ganizations, and nongovernmental organizations, as ap- |
| 23 | propriate. |

